2022 Bristol Myers Squibb Scholarship to Empower Young Leaders Around the World

0 Comments

Deadline: 5-Jan-22

The One Young World is currently accepting applications for the 2022 Bristol Myers Squibb Scholarship to identify and empower young leaders who are improving medical outcomes for vulnerable communities and transforming lives through science.

Bristol Myers Squibb scholars are social entrepreneurs, activists, health professionals and more, who are paving the way for a world with a more inclusive and innovative healthcare sector and a shared mindset to serve patients.

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. They are focused on the core therapeutic areas and are pursuing multiple drug platforms across these areas with a goal of transforming patients’ lives through science.

Benefits

Bristol Myers Squibb Scholars will receive

  • Access to the One Young World Summit 2022 in Tokyo, Japan which takes place from 16-19 May.
  • Hotel accommodation between 15 – 19 May 2022.
  • The cost of travel to and from Tokyo.
  • Catering which includes breakfast, lunch and dinner.
  • Transport between Summit accommodation and the Summit venue.
Eligibility Criteria
  • Aged 18 – 30 *.
  • Nationals of all countries are eligible to apply for this scholarship.
  • Demonstrated capacity for leadership.
  • Understanding of key local and / or global issues.
  • Applicant s must demonstrate positive impact in providing access to healthcare and supporting vulnerable communities.

* Most delegates are between the age of 18 and 30. The One Young World team will consider applications from those who are older than 30, pending demonstration of appropriate personal impact, initiative, and willingness to engage. They are not able to accept applications from those who will be aged under 18 at the time of the Summit.

For more information, visit https://www.oneyoungworld.com/scholarships/bristol-myers-squibb/2022

Tags: